查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858986

核醫市場機會、成長促進因素、產業趨勢分析及預測（2025-2034年）

Nuclear Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 162 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球核醫市場價值為 164 億美元，預計到 2034 年將以 15.2% 的複合年成長率成長至 695 億美元。

核子醫學市場 - IMG1

核子醫學的快速成長受到多種因素的推動，包括癌症和心臟疾病發病率的上升、靶向放射性核素療法的日益普及、影像技術的不斷創新以及人口老化的加劇。核子醫學在現代醫療保健中發揮著至關重要的作用，它提供了一種非侵入性的診斷和治療多種疾病的方法。放射性藥物的使用能夠提供傳統影像技術往往無法捕捉到的分子層面的詳細資訊。隨著全球對精準醫療的日益重視，將放射性同位素直接輸送到病變細胞的療法因其能夠最大限度地減少對健康組織的損傷而備受關注。診療一體化技術的進步、人工智慧驅動的醫療工具的擴展、混合影像系統的發展以及發展中國家需求的成長，都顯著推動了市場的發展。診斷和標靶治療的結合正逐漸成為該領域的核心，為進一步在全球範圍內推廣應用和獲得監管部門的批准奠定了基礎。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 164億美元
預測值 695億美元
複合年成長率 15.2%

2024年，診斷領域佔據了66.1%的市場佔有率，這主要得益於對疾病早期識別需求的成長以及核成像工具的進步。 PET和SPECT等技術已成為檢測癌症、心血管併發症和神經系統疾病的標準方法，其高精度結果有助於疾病分期和監測。臨床上對核診斷日益成長的依賴性繼續鞏固了該領域的領先地位。

至2034年，心臟病學應用領域將以15.4%的複合年成長率成長。心臟疾病病例的增加，以及核子造影技術在心臟評估（例如心肌灌注研究）中的應用日益廣泛，共同推動了這一穩定成長。放射性示蹤劑和掃描系統的改進進一步提升了診斷效果和臨床效率。

2024年，北美核醫市佔率達50.9%。該地區癌症和慢性疾病的高發生率，加上完善的醫療保健系統和較高的預防性診斷意識，持續推動核醫學的普及應用。 PET和SPECT在醫院和影像中心的廣泛應用鞏固了其區域領先地位。此外，病患教育的不斷加強和對早期介入的重視也進一步提升了市場滲透率。

全球核子醫學市場的主要參與者包括西門子醫療、康德樂醫療、Curium Pharma、波士頓科學、Jubilant Pharma、太陽製藥、RadioMedix、Actinium Pharmaceuticals、Lantheus（SHINE Technologies）、GE醫療、Sirtex、Bracco、諾華、RLS Radiopharmacies和Theragenics。活躍於核子醫學市場的公司正致力於透過創新、合作和垂直整合來增強其競爭優勢。一項主要策略是投資研發，以開發新型放射性藥物並拓展其在腫瘤學、心臟病學和神經病學領域的應用產品線。一些公司也與學術機構、醫院和合約研究組織合作，以加速臨床試驗並擴大實際應用範圍。

目錄

第1章：方法論與範圍

第2章：執行概要

第3章：行業洞察

  • 產業生態系分析
  • 產業影響因素
    • 成長促進因素
      • 癌症和心血管疾病發生率不斷上升
      • 對早期準確疾病診斷的需求日益成長
      • PET和SPECT影像系統的技術進步
      • 擴大放射性藥物的治療應用
      • 政府的支持性措施和資助計劃
    • 產業陷阱與挑戰
      • 核子醫學手術和設備成本高昂。
      • 放射性同位素半衰期短且數量有限
    • 市場機遇
      • 標靶放射性核種療法的應用日益廣泛
      • 混合成像技術的進步
      • 增加新型放射性藥物的研究
  • 成長潛力分析
  • 報銷方案
  • 監管環境
    • 北美洲
    • 歐洲
  • 技術格局
    • 當前技術趨勢
    • 新興技術
  • 管道分析
  • 未來市場趨勢
  • 價值鏈分析
  • 波特的分析
  • PESTEL 分析
  • 差距分析

第4章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
    • 全球的
    • 北美洲
    • 歐洲
  • 競爭定位矩陣
  • 主要市場參與者的競爭分析
  • 關鍵進展
    • 併購
    • 合作夥伴關係與合作
    • 新產品發布
    • 擴張計劃

第5章：市場估算與預測：依產品分類，2021-2034年

  • 主要趨勢
  • 診斷
    • 單光子發射電腦斷層掃描（SPECT）同位素
      • TC-99m
      • I-123
      • GA-67
      • TL-201
      • 其他SPECT同位素
    • 正子斷層掃描（PET）同位素
      • F-18
      • RB-82
      • 其他PET同位素
  • 療法
    • BETA放射體
      • I-131
      • 盧-177
      • Y-90
      • SM-153
      • Re-186
      • 其他BETA發射體
    • 近距離放射治療同位素
      • 銥-192
      • 碘-125
      • 銫-131
      • 鈀-103
      • 其他近距離放射治療同位素
    • 阿爾法發射體
      • RA-223
      • 其他α發射體

第6章：市場估算與預測：依應用領域分類，2021-2034年

  • 主要趨勢
  • 神經病學
  • 心臟病學
  • 腫瘤學
  • 甲狀腺
  • 肺科
  • 其他應用

第7章：市場估算與預測：依最終用途分類，2021-2034年

  • 主要趨勢
  • 醫院
  • 診斷中心
  • 研究機構
  • 其他最終用途

第8章：市場估算與預測：依地區分類，2021-2034年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第9章：公司簡介

  • Actinium Pharmaceuticals
  • Boston Scientific
  • Bracco
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus (SHINE Technologies)
  • Novartis
  • RadioMedix
  • RLS Radiopharmacies
  • Siemens Healthineers
  • Sirtex
  • Sun Pharma
  • Theragenics
簡介目錄
Product Code: 12229

The Global Nuclear Medicine Market was valued at USD 16.4 billion in 2024 and is estimated to grow at a CAGR of 15.2% to reach USD 69.5 billion by 2034.

Nuclear Medicine Market - IMG1

The rapid growth is being fueled by several factors, including rising rates of cancer and heart-related illnesses, increasing use of targeted radionuclide therapies, ongoing innovation in imaging technologies, and a steadily aging population. Nuclear medicine plays a vital role in modern healthcare by offering non-invasive methods for diagnosing and treating a wide range of conditions. Using radiopharmaceuticals enables detailed molecular-level insights that traditional imaging techniques often fail to capture. With increasing global emphasis on precision medicine, therapies that deliver radioactive isotopes directly to diseased cells are gaining prominence due to their ability to minimize harm to healthy tissue. Advances in theranostics, expansion of AI-driven healthcare tools, growth in hybrid imaging systems, and a rise in demand across developing regions are significantly boosting the market. The combination of diagnostics and targeted therapies is evolving into a central focus in this field, setting the stage for further global adoption and regulatory approval.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$16.4 Billion
Forecast Value$69.5 Billion
CAGR15.2%

In 2024, the diagnostics segment held a 66.1% share, supported by growing demand for early disease identification and advancements in nuclear imaging tools. Techniques such as PET and SPECT have become standard for detecting cancer, cardiovascular complications, and neurological disorders, offering high-accuracy results that assist with staging and monitoring. This rising clinical reliance on nuclear diagnostics continues to anchor segmental dominance.

The cardiology application segment will grow at a CAGR of 15.4% through 2034. Increasing cases of heart conditions, coupled with the rising adoption of nuclear imaging for cardiac assessments such as myocardial perfusion studies, are contributing to this steady growth. Enhancements in radiotracers and scanning systems are further improving diagnostic outcomes and clinical efficiency.

North America Nuclear Medicine Market held a 50.9% share in 2024. The region's significant prevalence of cancer and chronic illnesses, combined with a well-established healthcare system and high awareness of preventive diagnostics, continues to drive the adoption of nuclear medicine. Widespread usage of PET and SPECT across hospitals and imaging centers supports regional leadership. Additionally, growing patient education and focus on early intervention are amplifying market penetration.

Key players in the Global Nuclear Medicine Market include Siemens Healthineers, Cardinal Health, Curium Pharma, Boston Scientific, Jubilant Pharma, Sun Pharma, RadioMedix, Actinium Pharmaceuticals, Lantheus (SHINE Technologies), GE Healthcare, Sirtex, Bracco, Novartis, RLS Radiopharmacies, and Theragenics. Companies active in the nuclear medicine market are focusing on a blend of innovation, partnerships, and vertical integration to reinforce their competitive edge. A primary strategy involves investing in R&D to create novel radiopharmaceuticals and expand the pipeline for oncology, cardiology, and neurology applications. Several players are also collaborating with academic institutions, hospitals, and contract research organizations to accelerate clinical trials and broaden real-world adoption.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Application trends
    • 2.2.4 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cancer and cardiovascular diseases
      • 3.2.1.2 Increasing demand for early and accurate disease diagnosis
      • 3.2.1.3 Technological advancements in PET and SPECT imaging systems
      • 3.2.1.4 Expanding therapeutic applications of radiopharmaceuticals
      • 3.2.1.5 Supportive government initiatives and funding programs
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of nuclear medicine procedures and equipment
      • 3.2.2.2 Short half-life and limited availability of radioisotopes
    • 3.2.3 Market opportunities
      • 3.2.3.1 Growing adoption of targeted radionuclide therapies
      • 3.2.3.2 Advancements in hybrid imaging technologies
      • 3.2.3.3 Increasing research in novel radiopharmaceuticals
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
    • 3.5.1 North America
    • 3.5.2 Europe
  • 3.6 Technology landscape
    • 3.6.1 Current technological trends
    • 3.6.2 Emerging technologies
  • 3.7 Pipeline analysis
  • 3.8 Future market trends
  • 3.9 Value chain analysis
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis
  • 3.12 Gap analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
  • 4.4 Competitive positioning matrix
  • 4.5 Competitive analysis of major market players
  • 4.6 Key developments
    • 4.6.1 Mergers & acquisitions
    • 4.6.2 Partnerships & collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Diagnostics
    • 5.2.1 Single photon emission computed tomography (SPECT) isotopes
      • 5.2.1.1 TC-99m
      • 5.2.1.2 I-123
      • 5.2.1.3 GA-67
      • 5.2.1.4 TL-201
      • 5.2.1.5 Other SPECT isotopes
    • 5.2.2 Positron emission tomography (PET) isotopes
      • 5.2.2.1 F-18
      • 5.2.2.2 RB-82
      • 5.2.2.3 Other PET isotopes
  • 5.3 Therapeutics
    • 5.3.1 Beta emitters
      • 5.3.1.1 I-131
      • 5.3.1.2 Lu-177
      • 5.3.1.3 Y-90
      • 5.3.1.4 SM-153
      • 5.3.1.5 Re-186
      • 5.3.1.6 Other beta emitters
    • 5.3.2 Brachytherapy isotopes
      • 5.3.2.1 Iridium-192
      • 5.3.2.2 Iodine-125
      • 5.3.2.3 Cesium-131
      • 5.3.2.4 Palladium-103
      • 5.3.2.5 Other brachytherapy isotopes
    • 5.3.3 Alpha emitters
      • 5.3.3.1 RA-223
      • 5.3.3.2 Other alpha emitters

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Neurology
  • 6.3 Cardiology
  • 6.4 Oncology
  • 6.5 Thyroid
  • 6.6 Pulmonary
  • 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Diagnostic centers
  • 7.4 Research institutes
  • 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Actinium Pharmaceuticals
  • 9.2 Boston Scientific
  • 9.3 Bracco
  • 9.4 Cardinal Health
  • 9.5 Curium Pharma
  • 9.6 GE Healthcare
  • 9.7 Jubilant Pharma
  • 9.8 Lantheus (SHINE Technologies)
  • 9.9 Novartis
  • 9.10 RadioMedix
  • 9.11 RLS Radiopharmacies
  • 9.12 Siemens Healthineers
  • 9.13 Sirtex
  • 9.14 Sun Pharma
  • 9.15 Theragenics